Sumitomo Mitsui DS Asset Management Company Ltd Increases Stake in Becton, Dickinson and Company $BDX

Sumitomo Mitsui DS Asset Management Company Ltd boosted its stake in Becton, Dickinson and Company (NYSE:BDX) by 1.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 38,111 shares of the medical instruments supplier’s stock after purchasing an additional 537 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Becton, Dickinson and Company were worth $6,565,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in BDX. GQG Partners LLC purchased a new position in shares of Becton, Dickinson and Company during the first quarter valued at approximately $689,833,000. Vanguard Group Inc. increased its stake in shares of Becton, Dickinson and Company by 4.7% during the first quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier’s stock valued at $6,414,322,000 after buying an additional 1,259,750 shares during the period. Nuveen LLC purchased a new position in shares of Becton, Dickinson and Company during the first quarter valued at approximately $211,097,000. GAMMA Investing LLC increased its stake in shares of Becton, Dickinson and Company by 29,654.0% during the first quarter. GAMMA Investing LLC now owns 744,445 shares of the medical instruments supplier’s stock valued at $170,523,000 after buying an additional 741,943 shares during the period. Finally, Massachusetts Financial Services Co. MA increased its stake in shares of Becton, Dickinson and Company by 10.8% during the first quarter. Massachusetts Financial Services Co. MA now owns 6,843,856 shares of the medical instruments supplier’s stock valued at $1,567,654,000 after buying an additional 667,957 shares during the period. 86.97% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have recently issued reports on BDX. Wells Fargo & Company boosted their target price on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a research note on Friday, August 8th. Barclays reduced their price target on Becton, Dickinson and Company from $261.00 to $241.00 and set an “overweight” rating on the stock in a research note on Tuesday, June 3rd. Argus upped their price target on Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Morgan Stanley upped their price target on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Finally, Piper Sandler reaffirmed a “neutral” rating and issued a $200.00 price target (up from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Four equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Becton, Dickinson and Company currently has a consensus rating of “Hold” and an average target price of $213.30.

Becton, Dickinson and Company Trading Down 0.6%

Becton, Dickinson and Company stock opened at $187.27 on Friday. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. The business’s fifty day simple moving average is $187.65 and its two-hundred day simple moving average is $190.39. Becton, Dickinson and Company has a 12 month low of $163.33 and a 12 month high of $251.99. The company has a market capitalization of $53.68 billion, a price-to-earnings ratio of 33.68, a price-to-earnings-growth ratio of 1.52 and a beta of 0.27.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, topping the consensus estimate of $3.40 by $0.28. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The business had revenue of $5.51 billion for the quarter, compared to the consensus estimate of $5.50 billion. During the same period in the previous year, the company posted $3.50 earnings per share. The company’s revenue for the quarter was up 10.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. As a group, equities analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th will be issued a $1.04 dividend. This represents a $4.16 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend is Monday, September 8th. Becton, Dickinson and Company’s payout ratio is 74.82%.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,185 shares of the business’s stock in a transaction on Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the sale, the executive vice president directly owned 4,887 shares of the company’s stock, valued at approximately $881,077.23. The trade was a 19.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Claire Fraser sold 917 shares of the company’s stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the transaction, the director directly owned 22,226 shares in the company, valued at approximately $4,167,375. The trade was a 3.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 2,965 shares of company stock worth $551,536 over the last three months. Corporate insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.